Examples of 'safinamide' in a sentence
Meaning of "safinamide"
safinamide (noun): A medication used to treat Parkinson's disease. It works by helping to restore the balance of certain natural substances in the brain
Show more definitions
- A drug under investigation for the treatment of Parkinson's disease.
How to use "safinamide" in a sentence
Basic
Advanced
safinamide
Safinamide may be taken with or without food.
Xadago contains the active substance safinamide.
Safinamide is eliminated mainly in the urine.
No clinical data for safinamide on exposed pregnancies is available.
Safinamide should be taken with water.
The high absorption classifies safinamide as a highly permeable substance.
The raw safinamide or ralfinamide are then purified by crystallization.
Xadago is a medicine that contains the active substance safinamide.
The pharmacokinetics of safinamide are linear after single and repeated doses.
The active substance is safinamide.
Safinamide is the first antiparkinson medication to be approved for ten years.
Metabolite structure elucidation revealed three metabolic pathways of safinamide.
Substance safinamide methanesulfonate.
Women of childbearing potential should be advised not to become pregnant during safinamide therapy.
There is no known antidote to safinamide or any specific treatment for safinamide overdose.
See also
Safinamide does not appear to significantly induce or inhibit enzymes at clinically relevant systemic concentrations.
The pharmacodynamic effects of safinamide have not been assessed in children and adolescents.
Safinamide treatment has not been associated with any increase in the appearance of ICDs.
There was no significant difference in the occurrence of these effects between safinamide and placebo.
Safinamide should not be given to women of childbearing potential unless adequate contraception is practiced.
Combination therapy includes the administration of safinamide and one or more dopamine agonists.
Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.
Caution should be exercised when initiating treatment with safinamide in patients with moderate hepatic impairment.
Safinamide may transiently inhibit BCRP in vitro.
There is no experience taking Ongentys and safinamide together.
Safinamide is an anti-PD agent with multiple mechanisms of action.
Nevertheless when added to this DA agonist regiment safinamide was able to revert the impairment.
Safinamide and ralfinamide and in particular safinamide, are not cholinesterase inhibitors.
One mechanism of safinamide may be as a MAO-B inhibitor.
Safinamide acts through both dopaminergic and non-dopaminergic mechanisms of action.
There is no experience with opicapone when used concomitantly with the MAO-B inhibitor safinamide.
Safinamide should not be given with opioids ; some fatal reactions have occurred.
Your doctor may need to adjust your treatment ; safinamide used for Parkinson 's disease.
Safinamide inhibits OCT1 in vitro at clinically relevant portal vein concentrations.
The methods of treating Parkinson 's Disease disclosed, herein include administration of safinamide and a dopamine agonist.
Safinamide is associated with state-dependent inhibition of voltage-gated sodium Na.
Another combination therapy of the invention includes safinamide levodopa / PDI, a COMT inhibitor, and a dopamine agonist.
What Xadago contains - The active substance is safinamide.
The pharmacokinetics of safinamide are linear after single and repeated doses. No time-dependency was observed.
In another aspect, a combination therapy for PD includes safinamide and levodopa / PDI.
Treatment with safinamide should be started at 50 mg per day.
Another combination therapy of the invention includes safinamide levodopa / PDI, and a COMT inhibitor.
Safinamide undergoes almost complete metabolic transformation < 10 % of the administered dose was found unchanged in urine.
Another combination therapy of the invention includes safinamide as defined above levodopa / PDI and a dopamine agonist.
Safinamide transiently inhibits BCRP in the small intestine see section 4.5.
The improvement is particularly evident when safinamide is associated to a dopamine agonist Stocchi, F et al.
Safinamide use in patients with severe hepatic impairment is contraindicated ( see section 4.3 ).
Each film-coated tablet contains safinamide methansulfonate equivalent to 50 mg safinamide.
If patients progress from moderate to severe hepatic impairment safinamide should be stopped ( see section 4.4 ).
Experience of use of safinamide in patients over 75 years of age is limited.
